{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:53:43Z","timestamp":1773687223817,"version":"3.50.1"},"reference-count":19,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:00:00Z","timestamp":1607212800000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR073314"],"award-info":[{"award-number":["R01AR073314"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,11,20]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Pegloticase is used in severe refractory gout or in cases of intolerance to other urate-lowering therapies. We sought to evaluate the patterns of pegloticase use in the USA and the incidence of safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective descriptive study using data from two US commercial insurance claims databases (2010\u20132018). We identified new initiators of pegloticase with \u22651 gout diagnosis code in the 365-day baseline period prior to pegloticase initiation. We measured the number and duration of pegloticase infusions. We assessed the risk of anaphylaxis or anaphylactoid reactions, cardiovascular events, including myocardial infarction or stroke, and hospitalisation for heart failure (new onset or exacerbations) while undergoing pegloticase therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 2.9 million patients with \u22651 diagnosis of gout, we identified only 483 (179 in Optum and 304 in MarketScan) pegloticase initiators. The mean age and % female was 55.6 years, 10.9% for MarketScan and 60.6 years and 17.3% for Optum. Hypertension was present in up to 85%, diabetes mellitus in 38%, chronic kidney disease in 46% and heart failure in 21% of the patients. The median number of infusions was four and the duration of therapy was 3 months. During the mean 0.5-year follow-up time on pegloticase, there were 3 (0.6%) anaphylaxis, 7 (1.4%) composite cardiovascular, 31 (6.4%) heart failure hospitalisations and 3 (0.6%) deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pegloticase is rarely used in gout, and the median duration of pegloticase therapy was 3 months. There were few anaphylaxis events captured in this claims-based study, while heart failure hospitalisations were common.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-041167","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:57:53Z","timestamp":1607389073000},"page":"e041167","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study"],"prefix":"10.1136","volume":"10","author":[{"given":"Sarah K","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-3579","authenticated-orcid":false,"given":"Seoyoung C","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"2025121410395102000_10.12.e041167.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1001124"},{"key":"2025121410395102000_10.12.e041167.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.071229"},{"key":"2025121410395102000_10.12.e041167.3","first-page":"711-20","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"2025121410395102000_10.12.e041167.4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"American College of rheumatology guideline for the management of gout","volume":"2020","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025121410395102000_10.12.e041167.5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2025121410395102000_10.12.e041167.6","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.semarthrit.2020.04.011","article-title":"Pegloticase treatment of chronic refractory gout: update on efficacy and safety","volume":"50","author":"Schlesinger","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025121410395102000_10.12.e041167.7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/2042098617727714","article-title":"Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations","volume":"8","author":"Guttmann","year":"2017","journal-title":"Ther Adv Drug Saf"},{"key":"2025121410395102000_10.12.e041167.8","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130571"},{"key":"2025121410395102000_10.12.e041167.9","doi-asserted-by":"crossref","unstructured":"Khanna D , Fitzgerald JD , Khanna PP , et al . American College of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia, 2012.","DOI":"10.1002\/acr.21772"},{"key":"2025121410395102000_10.12.e041167.10","unstructured":"Fda . Krystexxa (Pegloticase) injection label, 2012. Available: www.fda.gov\/medwatch [Accessed 05 Aug 2020]."},{"key":"2025121410395102000_10.12.e041167.11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/pds.3505","article-title":"Validation of anaphylaxis in the food and drug administration's Mini-Sentinel","volume":"22","author":"Walsh","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121410395102000_10.12.e041167.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2006.05.010"},{"key":"2025121410395102000_10.12.e041167.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1396-8","article-title":"Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout","volume":"19","author":"Calabrese","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025121410395102000_10.12.e041167.14","doi-asserted-by":"publisher","DOI":"10.1186\/ar4497"},{"key":"2025121410395102000_10.12.e041167.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.09.033"},{"key":"2025121410395102000_10.12.e041167.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket293"},{"key":"2025121410395102000_10.12.e041167.17","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"2025121410395102000_10.12.e041167.18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121410395102000_10.12.e041167.19","unstructured":"FDA . Fda adds Boxed warning for increased risk of death with gout medicine Uloric (febuxostat) | FDA. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat [Accessed 28 Nov 2019]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-041167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:40:01Z","timestamp":1765737601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-041167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,7]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bmjopen-2020-041167"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-041167","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}